"For the AIPM, it’s crucial to monitor how new GMP approaches and initiatives impact regulatory timelines, drug registration, and patient access to modern therapies. The Association’s next step will be to develop a unified position and proposals for an EAEU GMP certificate for civilian products, to be discussed further with regulators," the AIPM stated.